The global hydrogel-based drug delivery system market is expected to experience significant growth in the coming years. Factors driving this growth include the increasing prevalence of chronic diseases such as cancer and diabetes, the rising demand for targeted drug delivery systems, and advancements in hydrogel technology. Hydrogel-based drug delivery systems offer numerous advantages such as sustained release of drugs, reduced toxicity, and improved efficacy. Moreover, increasing investments in research and development activities and the growing adoption of hydrogel-based drug delivery systems in various therapeutic applications are also contributing to market growth. However, the high cost of hydrogel-based drug delivery systems and the stringent regulatory requirements for their approval may hinder market growth. Overall, the hydrogel-based drug delivery system market is expected to witness significant growth in the coming years, driven by advancements in technology and growing demand for targeted drug delivery.
Hydrogel-Based Drug Delivery System Market
The Global is estimated to be valued at US$ 4,785.4 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).
Prominent Companies in the Hydrogel Based Drug Delivery System Industry:
Johnson & Johnson
Founded in 1886, Johnson & Johnson is an American multinational corporation that develops, manufactures, and sells healthcare products, medical devices, and pharmaceuticals. The company is headquartered in New Brunswick, New Jersey, and operates in over 60 countries worldwide. In January 2022, Johnson & Johnson announced a partnership with Affinivax to develop a next-generation vaccine using Affinivax's proprietary MAPS (Multiple Antigen Presenting System) platform and J&J's AdVac vaccine platform. The MAPS platform uses a hydrogel-based delivery system to improve the immune response to the vaccine.
Bausch & Lomb
Bausch & Lomb is a Canadian-based eye health products company founded in 1853. The company produces and sells contact lenses, lens care products, pharmaceuticals, and surgical instruments. Bausch & Lomb is headquartered in Laval, Quebec, and operates in over 50 countries worldwide. In December 2021, Bausch & Lomb announced the launch of their Synergi hydrogel-based contact lenses, which are designed to provide comfort and moisture for up to 16 hours of wear.
Ocular Therapeutix, Inc
Founded in 2006, Ocular Therapeutix, Inc is an American biopharmaceutical company that develops and commercializes innovative therapies for ocular diseases and conditions. The company is headquartered in Bedford, Massachusetts, and operates in the United States. In November 2021, Ocular Therapeutix announced positive topline results from their Phase 1 study of OTX-TIC, a hydrogel-based implant designed to deliver a sustained release of dexamethasone for the treatment of ocular inflammation and pain.